Our Archives section provides access to previously published issues, ensuring a comprehensive resource for researchers, practitioners, and educators.
Explore Past Issues
Volume 1
Issue 2 JULY– DECEMBER 2025
Volume 1 (Issue 2) JULY– DECEMBER 2025 Research Articles
Population Pharmacokinetic Modelling and Dose Optimisation of Vancomycin in Neonatal Intensive Care Unit Patients
Vol.1(2); Pages:1-7. Published on July-2025
Abstract
Developmental changes, organ immaturity, and rapid physiological changes make neonates in intensive care units (ICUs) have a large range of drug pharmacokinetics. The objective of this study was to build a population pharmacokinetic (PopPK) model of vancomycin in neonatal intensive care unit (NICU) and to minimize or maximize dose regimens to reach therapeutic trough concentrations. The NONMEM software was used to analyze data on 76 NICU patients and covariates including postnatal age, body weight, and serum creatinine were significantly found to affect clearance and volume of distribution. Bootstrap and visual predictive checks were used to get the final model validated. Simulations using a model suggested weight- and age-dependent dosing to exceed 85 percent target attainment in the therapeutic range between 10-20 mg/L. These findings speak in favour of personalized vancomycin dosing in neonatal groups and emphasize the significance of the PopPK tools in pediatric personalized dosing.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Optimization of Dosing of Intravenous Immunoglobulin for Pediatric Kawasaki Disease: A Pharmacokinetic-Pharmacodynamic Study
Vol.1(2); Pages:8-19. Published on October-2025
Abstract
Kawasaki disease (KD) is the most common acquired heart disease in children and treatment with intravenous immunoglobulin (IVIG) has significantly lowered the occurrence of coronary complication. Nevertheless, the dosing strategies still give a problem, especially among heavier children who can be under-exposed. The investigation was a pharmacokinetic-pharmacodynamic (PK-PD) trial that consisted of 64 children with acute KD at two European study sites. Serial plasma samples allowed the population PK models to be built, tying the exposure to IVIG with clinical effects, such as those to the coronary arteries and CRP normalization. Nominal 2 g/kg dosing resulted in therapeutic plasma exposure purposes in 78 percent of patients, but simulated effects showed unfavorable exposure in heavier patient classes. Individualized dosing strategies augmented the achievement of targets The adverse events were not of serious nature. These data justify pharmacometric-based dosing to maximize IVIG treatment in KD and improve cardiovascular outcomes.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Low-Dose Methotrexate Clinical Outcomes in Juvenile Idiopathic Arthritis as an Observational Cohort study with Multinational Data
Vol.1(2); Pages:20-31. Published on November-2025
Abstract
Methotrexate is the backbone disease-modifying antirheumatic drug (DMARD) in juvenile idiopathic arthritis (JIA), however, prospective observational evidence is scarce. This multinational cohort study assessed JIA children on low-dose methotrexate to a 24-month follow-up. The clinical response was measured using the American College of Rheumatology pediatric criteria, the growth outcome and safety measures. At 2 years, 63\% of patients had achieved 70\% response in the disease, whilst 21\% had clinical remission. Growth patterns were conserved as compared with the untreated historical cohorts. An increase in liver enzymes was observed in 8 percent of patients but was resolved by reduction of the dose; other side effects were mild in nature. Parental education interventions made treatment adherence to be more than 85%. These clinical observations validate the long-term effectiveness and tolerability of methotrexate and the importance of individualized dosing and monitoring in practice in pediatric rheumatology.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pediatric Formulation Development of Oral Voriconazole in Invasive aspergillosis: A Phase I Safety and Pharmacokinetics Study
Vol.1(2); Pages:32-42. Published on November-2025
Abstract
Voriconazole is the chief antifungal used against invasive aspergillosis, but its use in children is little by unpredictable pharmacokinetics and restricted formulations. This was a Phase I trial that examined the safety, pharmacokinetics and acceptability of a novel oral suspension in 28 children (2-12 years) with suspected or proven invasive aspergillosis. Patients were put on weight adjusted doses with the therapeutic drug monitoring. Pharmacokinetic characterization demonstrated an improvement in bioavailability and a decrease in interpatient variability relative to the current generations, improving drug exposure. There were no drugrelated severe toxicities; the most commonly reported mild toxicities were hepatotoxicity (14%) and visual disturbances (11%) that were reversible. Acceptability was good and palatability high and ease of administration in the younger children. These results suggest that pediatric-specific drug formulations can address the therapeutic shortcomings and yield enhanced antifungal conclusions in children vulnerable of acquiring invasive fungal infections.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Systematic Review and Meta-Analysis of Pain Management in Pediatrics with the Use of Intranasal Analgesics in Emergencies
Vol.1(2); Pages:43-52. Published on December-2025
Abstract
The management of pain is one of the clinical priorities in treating children in the emergency rooms especially when performing procedures including fracture reduction, repair of a laceration and burn. The meta-analysis involved 24 research studies encompassing 1,482 children evaluating the efficacy and safety of intranasal analgesics which were of fentanyl, ketamine, and dexmedetomidine. Intranasal fentanyl had similar analgesic effects to those of intravenous morphine, whereas ketamine was effective as an agent of procedural sedation. Dexmedetomidine had the potential to provide pre-procedural anxiolysis, but bradycardia merited attention. The reported adverse events predominantly were low intensity and short-lasting with no cases of respiratory depression requiring any intervention. Administration through the nose is rapid, resource-efficient, and not invasive, which indicates that it should be implemented in the practice of pediatric emergency room procedures.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Issue 1 JANUARY- JUNE 2025
Volume 1(Issue 1) JANUARY- JUNE 2025 Research Articles
Identifying Non-Standard Drug Applications from Atypical Information Sources
Vol.1(1); Pages:1-8. Published on June-2025
Abstract
Personalized medicine and new drug strategies make extensive use of medications being prescribed off their approved lists. Regular sources for pharmacovigilance rarely pick up the entire range of these practices, mainly those mentioned on social media, online forums or patient communities. We investigated techniques to identify unapproved drug applications from outside the usual health care sources. To meet this goal, NLP and machine learning are employed by the group to effectively detect and analyze examples of off-label use as a means to improve and increase real-world evidence for drug repurposing. An increased variety of data sources can reveal new behaviors in patients, support clinician research and recommend treatments not approved by regulators.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Assessing Drug Levels and Conducting Toxicological Screening using Dried Blood Spots
Vol.1(1); Pages:9-15. Published on June-2025
Abstract
Because it is convenient, affordable and gives reliable results, the use of dried blood spot (DBS) sampling is growing for quantifying drugs and poison in both clinical and legal investigations. The utility of this technology in TDM and toxicology makes it easier for teams in remote or limited-resource areas to collect, move and keep samples safe. Following this method, patients tend to follow treatments more closely, it makes large population research possible and it supports personalized care by making it possible to monitor medication levels often. With the help of LC-MS/MS, analytical methods have recently improved DBS analysis, making it more reliable for clinical pharmacology and toxicology use.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Investigating Community and Clinic Methods to Reduce Toxic Stress and Boost the Resilience of Infant Families
Vol.1(1); Pages:16-24. Published on June-2025
Abstract
It examines how hospitals, clinics and community agencies cooperate to lessen the effects of toxic stress and increase protective factors for families with infants. Exposure to many severe incidents during childhood leads to toxic stress which seriously affects a child’s growth and health in the future. Consequently, new integrated community-clinic programs now offer support that addresses trauma, helps with early intervention and supports parents who are at risk of problems. The aim of this research is to study different ways education is delivered in different places, covering culturally appropriate practices, fairness for all students and teamwork between sectors. The review of program reports, interviews with key parties and reviews from families showed that these actions help cut down on caregiver stress, boost the health of infants and support secure attachments. It also acknowledges that training has to be ongoing for everyone involved, funding sources should be planned for long into the future and health services should take social determinants into account. Results show that supporting families by including them in community efforts helps young children become more resilient and offers ways to improve family well-being during infancy and suggests improvements in relevant policies.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Adoption Of Impactful Healthcare Advancements by Child Health Specialists
Vol.1(1); Pages:25-31. Published on June-2025
Abstract
The success of applying new health ideas to treatment in pediatrics greatly affects the health of children. The subject includes many factors that play a role in deciding which new healthcare technologies, practices and models will be used by pediatricians. Despite the fact that telemedicine, digital health tools, expertise in diagnostics and immunizations are promising for pediatrics, putting them into practice meets challenges like inertia, lack of qualified staff, limited materials and opposition to new methods. In contrast, when you have strong support in the institution, professional development opportunities, effective teamwork across disciplines and good policies, implementation happens much faster. The purpose of this abstract is to understand the links between pediatric clinical roles and innovation diffusion, while looking at methods to support both uptake and continuity. Applying implementation science, it urgently promotes working with stakeholders, adapting designs for each community and ensuring evaluation systems address both scaling and equity. Being aware of how pediatricians deal with and drive the adoption of new medical technologies helps create healthcare systems able to better meet the health needs of children and adolescents in any resource setting.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Creating A Novel System That Uses Goal-Oriented Methodology to Improve the Management of Chronic Diseases
Vol.1(1); Pages:32-40. Published on June-2025
Abstract
Maintaining good health outcomes for people with chronic illnesses is challenging, mainly because of difficulties in getting them to follow treatment and remain involved. Most present-day health systems struggle to offer personalized and changing care for people with persistent health problems. The study looks at Goal-Directed Design as a person-focused strategy for conceptualizing and building a system that helps manage chronic diseases. Thanks to using user personas, scenario-based planning and iterative design thinking, the framework enables healthcare interventions to support what patients want to achieve emotionally, how they behave and what they need daily. A smart tracting system, feedback mechanism and interactive features are included to help users manage their health and guide healthcare providers with important insights. Testing the prototype and seeing how users interact with it suggests a large chance to improve satisfaction, compliance with treatment plans and clinical communication. This way of thinking restarts the care approach for those with chronic diseases and illustrates the strength of Goal-Directed Design in healthcare improvement. It suggests emerging ways in which technology could improve how chronic care is managed for patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
